Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), and connected persons, in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes rather than financial performance metrics.
Material Changes
On April 10, 2015, several Directors and PDMRs increased their interests in GSK Ordinary Shares. These increases resulted from the re-investment of dividends paid to shareholders on April 9, 2015. The transaction price was 1611.45 pence per Share.
- Sir Andrew Witty: 2,063.469 Shares
- Mr S A Hussain: 2,111.840 Shares
- Dr P J T Vallance: 1,192.237 Shares
- Ms C Thomas: 983.411 Shares
- Ms E Walmsley: 924.677 Shares
- Mr S Dingemans: 922.997 Shares
- Mr D S Redfern: 801.120 Shares
- Mr R G Connor: 233.946 Shares
- Mr P C Thomson: 336.617 Shares
- Dr M M Slaoui: 161.949 Shares
- Mrs K Thomson (Connected Person): 71.623 Shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the dividend reinvestment mechanism and the specific ex-dividend date of April 9, 2015.
- Confirm the share price of 1611.45 pence per Share on April 10, 2015.
- Review the total aggregate shareholding of the listed Directors and PDMRs to assess insider confidence levels.
- Check subsequent filings for any further changes in director interests or financial performance updates for the full quarter.